Livzon Pharmaceutical Group (LVZP.F) Stock Overview
Researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
LVZP.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Livzon Pharmaceutical Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.80 |
| 52 Week High | CN¥5.22 |
| 52 Week Low | CN¥3.80 |
| Beta | 0.24 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -17.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| LVZP.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | -1.4% |
| 1Y | n/a | 40.1% | 16.4% |
Return vs Industry: Insufficient data to determine how LVZP.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LVZP.F performed against the US Market.
Price Volatility
| LVZP.F volatility | |
|---|---|
| LVZP.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LVZP.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine LVZP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 8,878 | Daping Liu | www.livzon.com.cn |
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neurological field; and shenqi fuzheng injection and anti-viral granules for the traditional Chinese medicine field. It also produces APIs and intermediates, such as mevastatin, acarbose, teicoplanin, gentamycin sulfate, phenylalanine, vancomycin hydrochloride, daptomycin, milbemycin oxime, and ceftriaxone sodium, as well as diagnostic reagents such as diagnostic kits for IgM antibody to mycoplasma pneumonia; diagnostic kits for human immunodeficiency virus antibody; and livzon antinuclear antibody test kits.
Livzon Pharmaceutical Group Inc. Fundamentals Summary
| LVZP.F fundamental statistics | |
|---|---|
| Market cap | US$3.45b |
| Earnings (TTM) | US$289.80m |
| Revenue (TTM) | US$1.73b |
Is LVZP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LVZP.F income statement (TTM) | |
|---|---|
| Revenue | CN¥11.71b |
| Cost of Revenue | CN¥4.00b |
| Gross Profit | CN¥7.71b |
| Other Expenses | CN¥5.75b |
| Earnings | CN¥1.96b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.21 |
| Gross Margin | 65.84% |
| Net Profit Margin | 16.77% |
| Debt/Equity Ratio | 18.9% |
How did LVZP.F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/23 12:36 |
| End of Day Share Price | 2026/03/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Livzon Pharmaceutical Group Inc. is covered by 19 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Helena Qiu | CCB International Securities Limited |
| Yanyin Zhu | China International Capital Corporation Limited |
| You You Liu | China Stock Investment Research Co. Ltd. (DeepValue.online) |